CA Patent

CA2721489A1 — Use of antiarrhythmic dronedarone to prevent cardiovascular hospitalization or sudden death due to cardiovascular causes

Assigned to Sanofi Aventis France · Expires 2009-12-03 · 16y expired

What this patent protects

Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality.

USPTO Abstract

Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality.

Drugs covered by this patent

dronedarone-hydrochloride (DRONEDARONE HYDROCHLORIDE)

Patent Metadata

Patent number: CA2721489A1
Jurisdiction: CA
Classification: —
Expires: 2009-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.